NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) has engaged leading international contract research organisation (CRO) Biospective Inc. to undertake studies to support the development of EmtinB as a therapeutic treatment for Multiple sclerosis (MS).
Based in Montreal, Canada, Biospective specialises in preclinical and clinical neurology research with particular strengths in neurodegenerative conditions, including MS, Alzheimer’s disease, Amyotrophic Lateral Sclerosis, and Parkinson’s disease.
Biospective’s research facilities are state-of-the-art, offering world class expertise in imaging studies, behavioural testing, histology, and immunohistochemistry.
NeuroScientific’s CEO and Managing Director, Matt Liddelow, said Biospective is a global leader in neuroimaging, providing the broadest range of imaging modalities and quantitative measures in neurology research.
I’m very pleased to announce the partnership with industry leading CRO Biospective to conduct studies for NSB’s R&D programme in Multiple sclerosis,” Mr Liddelow said.
“In addition to their world class expertise, the range of imaging technologies offered by Biospective is unprecedented for preclinical neurology research and will aid in generating detailed data that will be of clinical significance in future clinical studies.”
MS is a progressive neurodegenerative disease characterised by chronic inflammatory responses, whereby activated immune cells migrate into the central nervous system (CNS) and attack the myelin sheath that surrounds nerve fibres and damage neurons, leading to disruption of normal cognitive, sensory, and motor function.
Currently approved MS drugs modulate inflammatory responses only and do not directly affect myelin production or neuronal survival. Global sales for approved MS drugs in 2020 was approximately US$22 billion.